Please login to the form below
cell and gene therapies
This page shows the latest cell and gene therapies news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca officially opens new R&D facility in UK
said. The Discovery Centre will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next-generation therapeutics, including nucleotide-based, gene-editing and cell ... therapies, said the
Latest news
-
Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network
UDG Healthcare company Ashfield has launched a new network offering an end-to-end approach for the commercialisation of cell and gene therapies. . ... Health. “EmerGENE is no different, and with over 1, 200 cell and gene therapy clinical trials
-
BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021
Novartis is providing support with a production site in the German city of Marburg, which is fully equipped for the production of recombinant proteins, as well as cell and gene therapies. ... Additional measures and discussions with potential partners to
-
bluebird bio to separate oncology and rare diseases units
Over the last decade, bluebird bio has pioneered development of gene and cell therapies for severe genetic diseases and oncology – delivering transformative outcomes for patients,” said Leschly. ... bluebird bio will continue to focus on delivering
-
Bayer strengthens cell and gene therapy focus with new platform
The new cell and gene therapy platform will house both AskBio and another of Bayer’s recently acquired firms, BlueRock Therapeutics, under one roof. ... area. “This is a defining moment for Bayer. Cell and gene therapies are leading innovation in
-
BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
The Marburg site is fully equipped for the production of recombinant proteins as well as cell and gene therapies, with Novartis having significantly invested in the site over the past five ... expertise,” said Sierk Poetting, chief financial officer
More from news
Approximately 3 fully matching, plus 54 partially matching documents found.
Latest Intelligence
-
EU cross-border healthcare
The clock is ticking to improve access to gene and cell therapies for rare diseases. ... A complex and little-known framework that fails to address the specificities of gene and cell therapies.
-
Rare genetic diseases – what’s in store for 2021?
In my opinion, these new pathways will establish themselves and be extended to other treatments, including cell and gene therapies. ... Mike Fraser is General Manager, EMEA at Novartis Gene Therapies. 16th February 2021. .
-
Keeping up with the developing regulatory requirements for gene and cell therapies
The first cell and gene therapies were developed to treat rare and fatal diseases, which is why patients were possibly more likely to accept higher-risk treatment options. ... must create manufacturing processes for cell and gene therapies that aren’t
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the first generation of gene and cell therapies. ... Many drug developers also have looked to engage and acquire companies with synergistic discovery-stage platforms to expand their portfolios to include next-generation and potentially curative therapies
-
Successful product commercialisation: what can we learn from the rare disease setting?
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies ... For novel therapies (including medicines aimed at rare
More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics. ... It is also charged with developing HCP engagement on gene silencing
-
Abeona Therapeutics appoints new additions to board of directors
Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and gene therapies for Novartis subsidiaries Systemix Inc.
-
Paul Blake joins Oxford BioMedica
He will head the clinical development of the company's pipeline of gene and cell therapies. ... therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... outcomes. This is truly unprecedented and more involved than previous solutions to the challenges facing a registry. Early
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
-
OPEN Health
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era.
-
Training the next generation of biotech leaders
Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from
-
Life at the end of the Brexit tunnel
An Advanced Therapies Treatment Centre to develop cell and gene therapies. ... Expansion of the Cell and Gene Therapy Manufacturing Centre in Stevenage.
OPEN Health
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Merck enters agreement with Hanmi for investigational NASH drug
- Novo Nordisk growth takes a hit with China deal
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- The gold standard of scientific evidence
- AbbVie creates new aesthetics division amid Allergan takeover
- EU approves bluebird bio’s CALD gene therapy Skysona
- Organon buys Forendo in $1bn deal
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
